tooluniverse-gwas-study-explorer
GWAS Study Deep Dive & Meta-Analysis
Compare GWAS studies, perform meta-analyses, and assess replication across cohorts
Overview
The GWAS Study Deep Dive & Meta-Analysis skill enables comprehensive comparison of genome-wide association studies (GWAS) for the same trait, meta-analysis of genetic loci across studies, and systematic assessment of replication and study quality. It integrates data from the NHGRI-EBI GWAS Catalog and Open Targets Genetics to provide a complete picture of the genetic architecture of complex traits.
Key Capabilities
- Study Comparison: Compare all GWAS studies for a trait, assessing sample sizes, ancestries, and platforms
- Meta-Analysis: Aggregate effect sizes across studies and calculate heterogeneity statistics
- Replication Assessment: Identify replicated vs novel findings across discovery and replication cohorts
- Quality Evaluation: Assess statistical power, ancestry diversity, and data availability
Use Cases
1. Comprehensive Trait Analysis
Scenario: "I want to understand all available GWAS data for type 2 diabetes"
Workflow:
- Search for all T2D studies in GWAS Catalog
- Filter by sample size and ancestry
- Extract top associations from each study
- Identify consistently replicated loci
- Assess ancestry-specific effects
Outcome: Complete landscape of T2D genetics with replicated findings and population-specific signals
2. Locus-Specific Meta-Analysis
Scenario: "Is the TCF7L2 association with T2D consistent across all studies?"
Workflow:
- Retrieve all TCF7L2 (rs7903146) associations for T2D
- Calculate combined effect size and p-value
- Assess heterogeneity (I² statistic)
- Generate forest plot data
- Interpret heterogeneity level
Outcome: Quantitative assessment of effect size consistency with heterogeneity interpretation
3. Replication Analysis
Scenario: "Which findings from the discovery cohort replicated in the independent sample?"
Workflow:
- Get top hits from discovery study
- Check for presence and significance in replication study
- Assess direction consistency
- Calculate replication rate
- Identify novel vs failed replication
Outcome: Systematic replication report with success rates and failed findings
4. Multi-Ancestry Comparison
Scenario: "Are T2D loci consistent across European and East Asian populations?"
Workflow:
- Filter studies by ancestry
- Compare top associations between populations
- Identify shared vs population-specific loci
- Assess allele frequency differences
- Evaluate transferability of genetic risk scores
Outcome: Ancestry-specific genetic architecture with transferability assessment
Statistical Methods
Meta-Analysis Approach
This skill implements standard GWAS meta-analysis methods:
Fixed-Effects Model:
- Used when heterogeneity is low (I² < 25%)
- Weights studies by inverse variance
- Assumes true effect size is the same across studies
Random-Effects Model (recommended when I² > 50%):
- Accounts for between-study variation
- More conservative than fixed-effects
- Better for diverse ancestries or methodologies
Heterogeneity Assessment:
The I² statistic measures the percentage of variance due to between-study heterogeneity:
I² = [(Q - df) / Q] × 100%
where Q = Cochran's Q statistic
df = degrees of freedom (n_studies - 1)
Interpretation Guidelines:
- I² < 25%: Low heterogeneity → fixed-effects appropriate
- I² = 25-50%: Moderate heterogeneity → investigate sources
- I² = 50-75%: Substantial heterogeneity → random-effects preferred
- I² > 75%: Considerable heterogeneity → meta-analysis may not be appropriate
Sources of Heterogeneity
Common reasons for high I²:
- Ancestry differences: Different allele frequencies and LD structure
- Phenotype heterogeneity: Trait definition varies across studies
- Platform differences: Imputation quality and coverage
- Winner's curse: Discovery studies overestimate effect sizes
- Cohort characteristics: Age, sex, environmental factors
Recommendations:
- Perform subgroup analysis by ancestry
- Use meta-regression to investigate sources
- Consider excluding outlier studies
- Apply genomic control correction
Study Quality Assessment
Quality Metrics
The skill evaluates studies based on:
1. Sample Size:
- Power to detect associations (80% power requires n > 10,000 for OR=1.2)
- Precision of effect size estimates
- Ability to detect modest effects
2. Ancestry Diversity:
- Single-ancestry vs multi-ancestry
- Population stratification control
- Transferability of findings
3. Data Availability:
- Summary statistics available for meta-analysis
- Individual-level data vs summary-level
- Imputation quality scores
4. Genotyping Quality:
- Platform density and coverage
- Imputation reference panel
- Quality control measures
5. Statistical Rigor:
- Genome-wide significance threshold (p < 5×10⁻⁸)
- Multiple testing correction
- Replication in independent cohort
Quality Tiers
Tier 1 (High Quality):
- n ≥ 50,000
- Summary statistics available
- Multi-ancestry or large single-ancestry
- Imputed to high-quality reference
- Independent replication
Tier 2 (Moderate Quality):
- n ≥ 10,000
- Standard GWAS platform
- Adequate power for common variants
- Some data availability
Tier 3 (Limited):
- n < 10,000
- Limited power
- May miss modest effects
- Use with caution
Best Practices
Before Meta-Analysis
- Check phenotype consistency: Ensure studies measure the same trait
- Verify ancestry overlap: High heterogeneity expected if ancestries differ
- Harmonize alleles: Align effect alleles across studies
- Quality control: Exclude low-quality studies or associations
Interpreting Results
- Genome-wide significance: p < 5×10⁻⁸ (Bonferroni for ~1M independent tests)
- Replication threshold: p < 0.05 in independent cohort
- Direction consistency: Effect should be same direction across studies
- Heterogeneity: I² > 50% suggests caution in interpretation
Common Pitfalls
❌ Don't:
- Meta-analyze without checking heterogeneity
- Ignore ancestry differences
- Over-interpret nominal p-values
- Assume replication failure means false positive
✅ Do:
- Always report I² statistic
- Perform sensitivity analyses
- Consider ancestry-stratified analysis
- Account for winner's curse in discovery studies
Limitations & Caveats
Data Limitations
- Incomplete Overlap: Studies may analyze different SNPs
- Cohort Overlap: Some cohorts participate in multiple studies (inflates significance)
- Publication Bias: Significant findings more likely to be published
- Winner's Curse: Discovery studies overestimate effect sizes
- Imputation Quality: Varies across studies and populations
Statistical Limitations
- Heterogeneity: High I² may preclude meaningful meta-analysis
- Sample Size Differences: Large studies dominate fixed-effects models
- Allele Frequency Differences: Same variant has different effects across ancestries
- Linkage Disequilibrium: Fine-mapping needed to identify causal variants
- Gene-Environment Interactions: Not captured in standard meta-analysis
Interpretation Guidelines
When I² > 75%:
- Meta-analysis results should be interpreted with extreme caution
- Investigate sources of heterogeneity systematically
- Consider ancestry-specific or subgroup analyses
- Descriptive comparison may be more appropriate than meta-analysis
When Studies Conflict:
- Check for methodological differences
- Verify phenotype definitions match
- Investigate population stratification
- Consider conditional analysis
Scientific References
Key Publications
-
GWAS Best Practices:
- Visscher et al. (2017). "10 Years of GWAS Discovery" American Journal of Human Genetics 101(1): 5-22
- PMID: 28686856
- DOI: 10.1016/j.ajhg.2017.06.005
-
Meta-Analysis Methods:
- Evangelou & Ioannidis (2013). "Meta-analysis methods for genome-wide association studies and beyond" Nature Reviews Genetics 14: 379-389
- PMID: 23657481
-
Heterogeneity Interpretation:
- Higgins et al. (2003). "Measuring inconsistency in meta-analyses" BMJ 327: 557-560
- PMID: 12958120
-
Multi-Ancestry GWAS:
- Peterson et al. (2019). "Genome-wide Association Studies in Ancestrally Diverse Populations" Nature Reviews Genetics 20: 409-422
- PMID: 30926972
-
Replication Standards:
- Chanock et al. (2007). "Replicating genotype-phenotype associations" Nature 447: 655-660
- PMID: 17554299
Tools Used
GWAS Catalog API
gwas_search_studies: Find studies by traitgwas_get_study_by_id: Get detailed study metadatagwas_get_associations_for_study: Retrieve study associationsgwas_get_associations_for_snp: Get SNP associations across studiesgwas_search_associations: Search associations by trait
Open Targets Genetics GraphQL API
OpenTargets_search_gwas_studies_by_disease: Disease-based study searchOpenTargets_get_gwas_study: Detailed study information with LD populationsOpenTargets_get_variant_credible_sets: Fine-mapped loci for variantOpenTargets_get_study_credible_sets: All credible sets for studyOpenTargets_get_variant_info: Variant annotation and allele frequencies
Glossary
Association: Statistical relationship between a genetic variant and a trait
Credible Set: Set of variants likely to contain the causal variant (from fine-mapping)
Effect Size: Magnitude of genetic association (beta coefficient or odds ratio)
Fine-Mapping: Statistical method to identify causal variants within a locus
Genome-Wide Significance: p < 5×10⁻⁸, accounting for ~1M independent tests
Heterogeneity (I²): Percentage of variance due to between-study differences
L2G (Locus-to-Gene): Score predicting which gene is affected by a GWAS locus
LD (Linkage Disequilibrium): Non-random association of alleles at different loci
Meta-Analysis: Statistical combination of results from multiple studies
Replication: Independent confirmation of an association in a new cohort
Summary Statistics: Per-SNP statistics (p-value, beta, SE) from GWAS
Winner's Curse: Overestimation of effect size in discovery studies
Next Steps
After running this skill, consider:
- Fine-Mapping: Use credible sets from Open Targets to identify causal variants
- Functional Follow-Up: Investigate biological mechanisms of replicated loci
- Genetic Risk Scores: Calculate polygenic risk scores using validated loci
- Drug Target Identification: Use L2G scores to prioritize therapeutic targets
- Cross-Trait Analysis: Look for pleiotropy with related traits
Version History
- v1.0 (2026-02-13): Initial release with study comparison, meta-analysis, and replication assessment
Created by: ToolUniverse GWAS Analysis Team Last Updated: 2026-02-13 License: Open source (MIT)
More from wu-yc/labclaw
tooluniverse-chemical-safety
Comprehensive chemical safety and toxicology assessment integrating ADMET-AI predictions, CTD toxicogenomics, FDA label safety data, DrugBank safety profiles, and STITCH chemical-protein interactions. Performs predictive toxicology (AMES, DILI, LD50, carcinogenicity), organ/system toxicity profiling, chemical-gene-disease relationship mapping, regulatory safety extraction, and environmental hazard assessment. Use when asked about chemical toxicity, drug safety profiling, ADMET properties, environmental health risks, chemical hazard assessment, or toxicogenomic analysis.
19rowan
Cloud-based quantum chemistry platform with Python API. Preferred for computational chemistry workflows including pKa prediction, geometry optimization, conformer searching, molecular property calculations, protein-ligand docking (AutoDock Vina), and AI protein cofolding (Chai-1, Boltz-1/2). Use when tasks involve quantum chemistry calculations, molecular property prediction, DFT or semiempirical methods, neural network potentials (AIMNet2), protein-ligand binding predictions, or automated computational chemistry pipelines. Provides cloud compute resources with no local setup required.
18tooluniverse-drug-repurposing
Identify drug repurposing candidates using ToolUniverse for target-based, compound-based, and disease-driven strategies. Searches existing drugs for new therapeutic indications by analyzing targets, bioactivity, safety profiles, and literature evidence. Use when exploring drug repurposing opportunities, finding new indications for approved drugs, or when users mention drug repositioning, off-label uses, or therapeutic alternatives.
18rdkit
Cheminformatics toolkit for fine-grained molecular control. SMILES/SDF parsing, descriptors (MW, LogP, TPSA), fingerprints, substructure search, 2D/3D generation, similarity, reactions. For standard workflows with simpler interface, use datamol (wrapper around RDKit). Use rdkit for advanced control, custom sanitization, specialized algorithms.
17tooluniverse-clinical-guidelines
Search and retrieve clinical practice guidelines across 12+ authoritative sources including NICE, WHO, ADA, AHA/ACC, NCCN, SIGN, CPIC, CMA, CTFPHC, GIN, MAGICapp, PubMed, EuropePMC, TRIP, and OpenAlex. Covers disease management, cardiology, oncology, diabetes, pharmacogenomics, and more. Use when users ask about clinical guidelines, treatment recommendations, standard of care, evidence-based medicine, or drug-gene dosing recommendations.
17tooluniverse-protein-therapeutic-design
Design novel protein therapeutics (binders, enzymes, scaffolds) using AI-guided de novo design. Uses RFdiffusion for backbone generation, ProteinMPNN for sequence design, ESMFold/AlphaFold2 for validation. Use when asked to design protein binders, therapeutic proteins, or engineer protein function.
17